PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.34%
Negative revenue growth while RUN stands at 32.40%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
105.72%
Gross profit growth at 50-75% of RUN's 187.88%. Martin Whitman would question if cost structure or brand is lagging.
57.70%
EBIT growth above 1.5x RUN's 34.03%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
46.08%
Operating income growth 1.25-1.5x RUN's 34.03%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
30.28%
Net income growth under 50% of RUN's 97.39%. Michael Burry would suspect the firm is falling well behind a key competitor.
30.93%
EPS growth under 50% of RUN's 88.89%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
30.93%
Diluted EPS growth under 50% of RUN's 88.89%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.39%
Share reduction more than 1.5x RUN's 1.01%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.39%
Diluted share reduction more than 1.5x RUN's 0.82%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-27.51%
Negative OCF growth while RUN is at 85.06%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-15.58%
Negative FCF growth while RUN is at 2.54%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
1.68%
10Y revenue/share CAGR under 50% of RUN's 100.18%. Michael Burry would suspect a lasting competitive disadvantage.
-53.23%
Negative 5Y CAGR while RUN stands at 100.18%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-39.91%
Negative 3Y CAGR while RUN stands at 100.18%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-1801.75%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-208.25%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-14.01%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-845.00%
Negative 10Y net income/share CAGR while RUN is at 209.97%. Joel Greenblatt sees a major red flag in long-term profit erosion.
5.36%
Below 50% of RUN's 209.97%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-718.62%
Negative 3Y CAGR while RUN is 209.97%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-38.05%
Negative equity/share CAGR over 10 years while RUN stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-45.43%
Negative 5Y equity/share growth while RUN is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-48.50%
Negative 3Y equity/share growth while RUN is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.87%
AR growth is negative/stable vs. RUN's 18.43%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
3.93%
We show growth while RUN is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.70%
Asset growth well under 50% of RUN's 5.12%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-5.90%
We have a declining book value while RUN shows 4.58%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.60%
We’re deleveraging while RUN stands at 6.87%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.71%
Our R&D shrinks while RUN invests at 23.83%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
1.93%
SG&A growth well above RUN's 3.05%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.